Keryx Biopharmaceuticals Provides Update From Ongoing Zerenex™ (ferric citrate coordination complex) Long-Term Safety Extension Study in Patients With Hyperphosphatemia on Dialysis

Published: Nov 08, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, Nov. 8, 2013 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced preliminary, unaudited data from an ongoing 48-week safety extension study of Zerenex™ (ferric citrate coordination complex) the Company's drug candidate for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Only patients who had participated in, and successfully completed the 58-week, long-term Phase 3 study were eligible for enrollment into this safety extension study. This 48-week, open-label extension (OLE) study, which is not a regulatory requirement, is being conducted in 35 sites in the United States. The study commenced enrollment in August 2012 and is anticipated to be completed in the first half of 2014.

Help employers find you! Check out all the jobs and post your resume.

Back to news